4 recruiting, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Active not recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Withdrawn 1 |
Follow Metastatic Sarcomatoid Renal Cell Carcinoma: new trials by email Literature Review of Metastatic Sarcomatoid Renal Cell Carcinoma trials Research Report on Metastatic Sarcomatoid Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Clostridium butyricum CBM 588 Probiotic Strain, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2021-11-01 | 2026-03-05 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-28 |
Carcinoma, Renal Cell (6) · Clear-cell metastatic renal cell carcinoma (5) · Carcinoma, Transitional Cell (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1) · Urachal adenocarcinoma (1) · Urethral Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1)
Adenocarcinoma (6) · Carcinoma (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Kidney Diseases (6) · Kidney Neoplasms (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Urologic Neoplasms (6) · Urogenital Neoplasms (5)
Nivolumab (5) · Specimen Handling (5) · CTLA-4 Antigen (4) · Ipilimumab (4) · Magnetic Resonance Spectroscopy (4) · Biopsy (2) · cabozantinib (2) · Inulin (1) · tivozanib (1)
City of Hope Medical Center (3) · National Cancer Institute (NCI) (1) · Osel, Inc. (1) · University of Michigan Rogel Cancer Center (1)
United States (6) · Puerto Rico (1)
Sumanta K Pal (2) · Alex Chehrazi-Raffle, MD (1) · Andrea B Apolo (1) · Charles B Nguyen (1) · Ulka N Vaishampayan (1)
P30CA033572 (4), U10CA180821 (1)